Last reviewed · How we verify
Iloperidone and VHX-896
At a glance
| Generic name | Iloperidone and VHX-896 |
|---|---|
| Sponsor | Vanda Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions (PHASE1)
- Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iloperidone and VHX-896 CI brief — competitive landscape report
- Iloperidone and VHX-896 updates RSS · CI watch RSS
- Vanda Pharmaceuticals portfolio CI